As House Passes PFAS Action Act, BioLargo Takes Next Step in Commercializing Its PFAS Treatment System - Seite 2
BioLargo's AEC technology has been proven to remove more than 99% of PFAS from contaminated water, and, compared with carbon filtration systems, generates about one tenth the PFAS-laden waste and costs less to operate. Decreased waste minimizes the environmental and regulatory burdens associated with water treatment.
Tonya Chandler, Director of Strategic Marketing and Business Development at BioLargo, said "With the passing of the PFAS Action Act of 2021 by the House of Representatives, PFAS regulations are just around the corner. BioLargo is in a perfect position to launch its revolutionary PFAS removal system into the market. The AEC produces significantly less waste than traditional systems making it a superior solution in this regulatory environment."
Learn more about BioLargo's AEC treatment through its engineering division at www.biolargoengineering.com/biolargo-aec
Contact Tonya Chandler for more information or to schedule treatment consultation at tonya.chandler@biolargo.com.
About BioLargo, Inc.
BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater
treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust
pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity
through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded
grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website
at www.BioLargo.com.
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those
about BioLargo's (the "Company") expectations regarding anticipated plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any
future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company's business, results of
operations, financial condition, and stock price; the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the
ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of
products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the
Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is
included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's
most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of
their respective dates.